SCHEMBL31247484

SCHEMBL31247484

CC(c1ccc(Nc2cc(Nc3ncccc3S(C)(=O)=O)ncn2)nc1)N1CCCC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ JAK1 P23458 5/20 0.38
▸ TYK2 P29597 5/20 0.38
▸ BRAF P15056 2/20 0.37
▸ TNNI3K Q59H18 2/20 0.37
▸ OGA O60502 4/20 0.36
▸ JAK2 O60674 4/20 0.35
▸ KCNH2 Q12809 3/20 0.35
▸ KIT P10721 2/20 0.35
▸ MEN1 O00255 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ ALOX15 P16050 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ PIK3CA P42336 2/20 0.34
▸ MTOR P42345 1/20 0.34
▸ JAK3 P52333 1/20 0.33
▸ EGFR P00533 1/20 0.33
▸ CHRM2 P08172 1/20 0.33
▸ CHRM1 P11229 1/20 0.33
▸ CCNT1 O60563 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31247753 1.00 JAK1 (0.38) JAK1TYK2BRAFTNNI3KOGA
SCHEMBL31247672 0.88 TYK2 (0.36) JAK1TYK2BRAFTNNI3KOGA
SCHEMBL31247462 0.87 TYK2 (0.37) JAK1TYK2BRAFTNNI3KJAK2
SCHEMBL31247715 0.87 TYK2 (0.37) JAK1TYK2BRAFTNNI3KJAK2
SCHEMBL31247569 0.87 TYK2 (0.37) JAK1TYK2BRAFTNNI3KJAK2
SCHEMBL31247677 0.86 TYK2 (0.37) JAK1TYK2BRAFTNNI3KJAK2
SCHEMBL31247595 0.86 TYK2 (0.35) JAK1TYK2BRAFTNNI3KJAK2
SCHEMBL31396641 0.85 JAK1 (0.36) JAK1TYK2BRAFTNNI3KOGA
SCHEMBL31247614 0.85 JAK1 (0.36) JAK1TYK2BRAFTNNI3KOGA
SCHEMBL31247522 0.83 JAK1 (0.41) JAK1TYK2BRAFTNNI3KJAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4719394-A2 INHIBITORS OF TYK2 Atomwise Inc. (US) 2026-04-08 — — EP disclosed
US-20260048051-A1 TREATMENT OF INFLAMMATORY BOWEL DISEASE ATOMWISE INC (US) 2026-02-19 — — US disclosed
US-20240425484-A1 INHIBITORS OF TYK2 Atomwise Inc. 2024-12-26 — — US disclosed
WO-2024250010-A2 INHIBITORS OF TYK2 Atomwise Inc. (US) 2024-12-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260048051-A1 TREATMENT OF INFLAMMATORY BOWEL DISEASE TYK2, FRK, DYRK2 JAK1 9/4885TYK2 1/4885BRAF 598/4885
US-20240425484-A1 INHIBITORS OF TYK2 TYK2, LCK, JAK2 JAK1 5/4885TYK2 1/4885BRAF 381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback